content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Histogenics Corporation (HSGX)

1.95
0.03
(1.56%)
Sep 11, 4:00PM EDT
content_middle

Histogenics Corporation (HSGX), a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace.

HSGX offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

HSGX has an exclusive channel collaboration agreement with Intrexon Corporation (XON)  for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.

Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

Previous Close: 
1.92
Open: 
1.91
Bid: 
1.75
Ask: 
4.00
1yr Target Price: 
6.00
Day's Range: 
1.86 - 1.98
52wk Range: 
1.45 - 4.06
Volume: 
114011
Average Daily Volume: 
60529
Market Capitalization: 
43.86M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
22490000M
content_right